Protexa Therapeutics Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Protexa Therapeutics General Information


Developer of proprietary pharmaceutical products based on a platform of TGF-beta production stimulators. The company's lead product is a proprietary fixed-dose combination of droloxifene and clopidogrel, being developed for the treatment of cardiovascular disease, and in particular acute coronary syndromes.

Contact Information

Formerly Known As
Johns Therapeutics
Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 9 St Johns Street
  • Cambridgeshire
  • Duxford CB22 4RA
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Protexa Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 01-Jan-2012 Completed Generating Revenue
1. Early Stage VC Completed Startup
To view Protexa Therapeutics’s complete valuation and funding history, request access »

Protexa Therapeutics Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Total Medical Ventures Venture Capital Minority 000 0000 000000 0
To view Protexa Therapeutics’s complete investors history, request access »